Forte Capital LLC ADV Buys Shares of 8,916 Roche Holding AG (OTCMKTS:RHHBY)

Forte Capital LLC ADV purchased a new position in shares of Roche Holding AG (OTCMKTS:RHHBY) in the fourth quarter, Holdings Channel.com reports. The fund purchased 8,916 shares of the company’s stock, valued at approximately $323,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Pacer Advisors Inc. boosted its position in Roche by 1,937.5% in the fourth quarter. Pacer Advisors Inc. now owns 1,099,659 shares of the company’s stock valued at $39,841,000 after buying an additional 1,045,687 shares in the last quarter. Saratoga Research & Investment Management boosted its holdings in shares of Roche by 19.4% during the 3rd quarter. Saratoga Research & Investment Management now owns 2,268,479 shares of the company’s stock valued at $76,969,000 after acquiring an additional 368,444 shares in the last quarter. Tower Bridge Advisors acquired a new position in Roche in the 3rd quarter worth about $2,811,000. Ramirez Asset Management Inc. bought a new position in Roche in the third quarter valued at about $2,575,000. Finally, Cable Hill Partners LLC acquired a new stake in shares of Roche during the fourth quarter valued at about $464,000.

Roche Stock Performance

Shares of OTCMKTS RHHBY traded up $0.57 during trading on Friday, reaching $29.83. The company had a trading volume of 4,829,456 shares, compared to its average volume of 4,474,277. The company’s fifty day moving average price is $31.62 and its 200-day moving average price is $33.44. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.75. Roche Holding AG has a 12 month low of $29.20 and a 12 month high of $40.48.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Argus reaffirmed a “hold” rating on shares of Roche in a research note on Monday, March 4th. Morgan Stanley cut shares of Roche from an “equal weight” rating to an “underweight” rating in a research report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $40.00.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.